So not a transplant nephrologist but the basics of immunosuppression are tested on the general renal boards. I will give my non-transplant nephrologist's summary on the literature for these agents here briefly. Any full time academic nephrologists on here can please feel free to correct this part-time private practice nephrologist's summary of the literature (though I was briefly on academic faculty. Now I am on private practice voluntary faculty with the fellowships at the hospital I am credentialed at) .
ATG - Rabbit or Horse - purified gamma globulin obtained by immunizing horses / rabbits with human lymphocytes. Cytotoxic antibodies to various CDs on T and B lymphocytes. Depletes peripheral lymhocytes via complement mediated lysis and clearance by the RES.
Alemtuzumab is depleting protein that is an anti CD52humanizied monoclonal antibody. CD52 is found on all B and T cells, macrophages, NK cells and some granulocytes. The alemtuzumab CD25 complex triggers antibody dependent lysis - the depletion of lymphocytes can persist for one year until the immune system is fully reconstituted
Basixilimab is a non-depleting protein that is a chimeric human/mouse monoclonal antibody that competitively inhibits the activation of lymphocytes by IL-2.
BPAR - Biopsy proven acute rejection
DGF - Delayed graft function
Brennan DC et al NEJM 2006 compared Basiliximab vs rATG in high risk recipients (more HLA mismatches) and showed that there are similar composite end point of BPAR , DGF , allograft / patient survival. Subanalysis showed significantly lower rates of BPAR associated with r-ATG
But there was significantly higher rates of myelosuppression and overall infections seen with r-ATG.
Hanaway MJ et al 2011 compared Alemtuzumab vs Basilixmab in low risk patients and Alemtuzumab vs rATG in high risk patients
Efficacy vs basixilimab showed lower rates of BPAR at 6,12, and 36 months with alemtuzumab with a composite endpoint of freedom from rejection, graft loss or death was significantby better at 3 years with alemtuzumab. But there were lower rates of serious infectious complications seen with basiliximab.
Efficacy vs rATG showed the composite endpoint of freedom from rejection, graft loss or death was similar between both agents. But there were overall more infectious disease seen with rATG but similar rates of serious infectious complications.
All three can be used for induction
Only basiximab can be used for maintenance immunosuppression
only Alemtuzumab and rATG/eATG can be use for treatment of rejection
This is a figure from Matas et al 2015 detailing current trends in antibody induction use in kidney transplantation.
The transplant nephrologists I rotated under as a fellow usually favored basiliximab for a patient with good 6/6 match and low KPI score.
They tended to use rATG otherwise for HLA mismatched kidneys and/or high KPI.
They also did not tend to prefer to use alemtuzumab due to perceived more serious side effects in their experience.
but hey im not a transplant neph and i dont order these things so im sure there are more nuances than that. I'm sure this is all center specific.